Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Committee hears emotional appeals for 'Hope for Missouri Patients' bill to expand access to individualized therapies
Loading...
Summary
Supporters told personal stories and urged passage of HB 2,643, which would create a pathway for individualized and compassionate-use treatments for rare and life‑threatening conditions; the sponsor and witnesses said the law would complement, not replace, clinical trials and that insurers would not be mandated to pay.
Representative Stennett introduced House Bill 2,643 — referred to in testimony as the Hope for Missouri Patients Act — to create a legal pathway for physicians and eligible facilities to provide individualized or bespoke therapies to patients with rare or life‑threatening conditions when conventional options are unavailable.
Stennett framed the bill around patient stories: she described young patients with Duchenne muscular dystrophy and other rare diseases, and told the committee about families who traveled abroad for individualized chemotherapy. “Passing this legislation will create a pathway for our doctors in Missouri that they can use to help children like Maddie and Gianna and cancer patients like David and Nicole,” Stennett said.
Witnesses from policy groups and families urged the committee to act quickly. Taylor Walker of the Goldwater Institute said federal regulations are not well suited to rapidly evolving individualized therapies and that 16 states have passed similar reforms. A mother who identified herself as Christine described losing her 17‑year‑old daughter and said the bill could prevent future tragic outcomes by removing red tape.
Committee members sought technical clarifications. A member asked whether the bill covers investigational‑new‑drug (IND) research; Stennett said the bill is intended to allow compassionate‑use style access outside the standard trial system and that eligible facilities would be subject to human‑subjects protections (FWA rules). She noted insurance companies would not be required to pay and that patients might have to cover costs or receive support from manufacturers.
No organized opposition appears in the transcript; the committee recorded multiple supporters, including patient advocates and policy organizations. The hearing closed after testimony and a short Q&A; no committee vote or formal action was recorded.
